Philips Expands Light-Based AI Navigation for 3D Endovascular Guidance

How LumiGuide Advances Radiation-Free 3D Navigation in Image-Guided Therapy
In complex endovascular procedures where device orientation and radiation safety are central concerns, Philips has expanded commercial availability of LumiGuide 3D Device Guidance — the world’s first AI-enabled, light-based 3D navigation solution — across Europe and the United States. Announced at RSNA 2025, this broader rollout delivers a radiation-free* navigation method that replaces continuous X-ray with optical visualization, while maintaining full compatibility with advanced image-guided therapy systems.

Real-Time 3D Visualization Using Light Instead of Continuous X-Ray
LumiGuide uses Philips Fiber Optic RealShape (FORS) technology to visualize wires and compatible catheters in real time and in 3D, without X-ray. Light reflected along the integrated optical fiber produces high-resolution, full-color views from any angle, giving physicians instant orientation inside the vasculature during complex interventions. AI rapidly aligns the image to the patient’s anatomy for precise navigation, supporting cases such as aortic repair, which can be performed 37% faster and with up to 56% DAP reduction1.

Clinical users have reported substantial workflow gains, including dramatically reduced fluoroscopy pedal time.

Integration with the Azurion Platform
LumiGuide is fully integrated with the Azurion image-guided therapy platform, which treats more than 6.4 million patients annually across over 80 countries2.

This integration allows clinicians to combine light-based navigation, low-dose imaging, intelligent guidance, and procedural workflow tools in a unified environment. Together with other AI-enabled technologies such as DeviceGuide and VeriSight 3D ICE, LumiGuide extends the capabilities of minimally invasive therapy through real-time insight and enhanced navigational precision.

Expanding Availability and Clinical Adoption
Following a limited release in late 2023, LumiGuide will be commercially available in major European markets and the United States beginning January 2026. The system has already supported more than 2,000 clinical procedures2.

Philips continues to invest in evidence generation to help clinicians optimize LumiGuide’s use across a broad range of vascular applications.

Advancing Low- and No-Dose Interventional Strategies
LumiGuide reinforces Philips’ leadership in low-dose and no-dose guidance technologies. Alongside solutions such as Azurion with ClarityIQ, DoseAware, EchoNavigator, and clinical programs including the RADIQAL trial, LumiGuide supports the transition toward safer, more efficient, and more sustainable image-guided therapy.

Sources
[1] Eric J. Finnesgard, Jessica P. Simons, Douglas W. Jones, Caitlin M. Sorensen, Tammy T. Nguyen, Andres Schanzer. Initial single-center experience using Fiber Optic RealShape guidance in complex endovascular aortic repair, Journal of Vascular Surgery, November 12, 2022. https://doi.org/10.1016/j.jvs.2022.11.041
[2] Data on file at Philips
* While navigation with LumiGuide itself involves no radiation exposure, some clinical procedures may incorporate limited X-ray imaging for initial anatomical visualization.
** LumiGuide has FDA clearance and CE marking and will be commercially available for order in the United States and Europe starting January 2026.
*** The opinions and clinical experiences presented herein are specific to the featured topic(s), are not linked to any specific patient and are for information purposes only. The medical experience(s) derived from these topics may not be predictive of all patients. Individual results may vary depending on a variety of patient-specific attributes and related factors. Nothing in this presentation is intended to provide specific medical advice or to take the place of written law or regulations.

www.philips.com